Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma-Reference-Cited by-同舟云学术

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

Published:2014-01-23 Issue:7 Volume:5 Page:1779-1792
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Borsi Enrica¹,Perrone Giulia²,Terragna Carolina¹,Martello Marina¹,Dico Angela F.¹,Solaini Giancarlo³,Baracca Alessandra³,Sgarbi Gianluca³,Pasquinelli Gianandrea¹,Valente Sabrina¹,Zamagni Elena¹,Tacchetti Paola¹,Martinelli Giovanni¹,Cavo Michele¹

Affiliation:

1. Department of Experimental Diagnostic and Specialty Medicine (DIMES), “L. & A. Seràgnoli”, Bologna University School of Medicine, S. Orsola's University Hospital, Italy

2. Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology Department, Via Venezian 1, Milano, Italy

3. Department of Biomedical and Neuromotor Sciences, University of Bologna, Via Irnerio 48, Bologna, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells;Heliyon;2024-06

2. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients;Clinical and Experimental Medicine;2023-10-10

3. Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma;Frontiers in Oncology;2023-06-08

4. The role of bone marrow microenvironment on CAR‐T efficacy in haematologic malignancies;Scandinavian Journal of Immunology;2023-05-06

5. Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance;Cancers;2023-03-09